PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173347
Abstract: Long-term high-fat diet consumption causes obese-insulin resistance and cardiac mitochondrial dysfunction, leading to impaired left ventricular (LV) function. Atorvastatin effectively improved lipid profiles in obese patients. However, inadequate reduction in low density lipoprotein cholesterol (LDL-C)… read more here.
Keywords: fat diet; insulin; pcsk9 inhibitor; obese insulin ... See more keywords
PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: A case report.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2017.09.001
Abstract: Identification of a patient homozygous for familial defective apolipoprotein B-100(FDB) and successful treatment with PCSK9 inhibition. read more here.
Keywords: pcsk9 inhibitor; defective apolipoprotein; apolipoprotein 100; familial defective ... See more keywords
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2021.08.001
Abstract: BACKGROUND Adults with atherosclerotic cardiovascular disease (ASCVD) at very high-risk for recurrent events who have low-density lipoprotein cholesterol ≥ 70 mg/dL despite maximally-tolerated statin therapy are recommended to initiate ezetimibe or a proprotein convertase subtilisin/kexin type 9… read more here.
Keywords: pcsk9 inhibitor; inhibitor; initiation; ezetimibe pcsk9 ... See more keywords
GREATER LIKELIHOOD OF REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB, IN PATIENTS WITH HIGHER LP(A) LEVELS
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)30558-8
Abstract: There is genetic and epidemiological evidence demonstrating the association between Lp(a) levels and cardiovascular disease. While evolocumab reduces Lp(a) by 25-30%, the impact of PCSK9 inhibition on plaque at different Lp(a) levels is unknown. GLAGOV… read more here.
Keywords: regression coronary; greater likelihood; pcsk9 inhibitor; likelihood regression ... See more keywords
REAL-WORLD UTILIZATION AND DISCONTINUATION PATTERNS OF PCSK9 INHIBITOR USE AT A LARGE, COMMUNITY-BASED LIPID CLINIC
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)32387-3
Abstract: PCSK9 inhibitor (PCSK9i) use continues to rise; however, access is limited. Herein, we describe our experience at a cardiology-based community lipid clinic with a focus on payer origin and intolerance rates. Queries for the clinic… read more here.
Keywords: community; lipid clinic; pcsk9 inhibitor; cardiology ... See more keywords
PCSK9 INHIBITOR INITIATION AMONG VETERANS ACCORDING TO THE 2018 AHA/ACC BLOOD CHOLESTEROL GUIDELINES
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)30860-3
Abstract: Proprotein convertase subtilisin/kexin type 9 inhibitor antibodies (PCSK9i) have been shown prevent cardiovascular disease events in patients with atherosclerotic cardiovascular disease (ASCVD). Analyzing the characteristics of patients who initiate and do not initiate a PCSK9i… read more here.
Keywords: veterans according; pcsk9 inhibitor; inhibitor initiation; according 2018 ... See more keywords
Ultrasensitive Homogeneous Detection of PCSK9 and Efficacy Monitoring of the PCSK9 Inhibitor Based on Proximity Hybridization-Dependent Chemiluminescence Imaging Immunoassay.
Sign Up to like & getrecommendations! Published in 2023 at "Analytical chemistry"
DOI: 10.1021/acs.analchem.3c00121
Abstract: Accurate quantification of proprotein convertase subtilisin/kexin type 9 (PCSK9) in serum before and after the medication is helpful in grasping the evolution of PCSK9-related disease and evaluating the efficacy of PCSK9 inhibitors. Conventional approaches for… read more here.
Keywords: proximity hybridization; pcsk9; efficacy; chemiluminescence imaging ... See more keywords
Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thoracic Imaging"
DOI: 10.1097/rti.0000000000000666
Abstract: Purpose: Previous studies have shown positive effects of intensive low-density lipoprotein (LDL)-lowering therapy on atheroma volume using invasive intravascular ultrasound. This study describes the changes in coronary plaque composition on coronary computed tomography angiography in… read more here.
Keywords: angiography; year; plaque; volume ... See more keywords
Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Clinical Investigation"
DOI: 10.1111/eci.13766
Abstract: Cellular cholesterol efflux is a key step in reverse cholesterol transport that may impact on atherosclerotic cardiovascular risk. The process may be reliant on the availability of apolipoprotein (apo) B‐100‐containing lipoproteins to accept cholesterol from… read more here.
Keywords: effect pcsk9; cholesterol efflux; cholesterol; pcsk9 inhibitor ... See more keywords
PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca2+ regulation
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.15556
Abstract: Post‐menopausal women have a higher risk of developing cardiometabolic dysfunction. Atorvastatin attenuates dyslipidaemia and cardiac dysfunction but it can have undesirable effects including increased risk of diabetes and myalgia. Currently, the proprotein convertase subtilisin/kexin type… read more here.
Keywords: pcsk9 inhibitor; inhibitor; prediabetic rats; function ... See more keywords
The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
Sign Up to like & getrecommendations! Published in 2021 at "Lipids in Health and Disease"
DOI: 10.1186/s12944-021-01536-3
Abstract: Background As an autosomal dominant disorder, familial hypercholesterolemia (FH) is mainly attributed to disease-causing variants in the low-density lipoprotein receptor ( LDLR ) gene. The aim of this study was to explore the molecular mechanism of… read more here.
Keywords: disease causing; pcsk9 inhibitor; 501c variant; treatment ... See more keywords